Form 4: Supernus Director Converts RSUs to Common Stock

Supernus Pharmaceuticals Director Charles W. Newhall III converted 4,475 restricted stock units into common stock.

Summary

• Director Charles W. Newhall III acquired 4,475 shares of Supernus Pharmaceuticals, Inc. common stock.
• This acquisition resulted from the vesting and settlement of 4,475 restricted stock units (RSUs).
• Following the transaction, Mr. Newhall III beneficially owns 124,119 shares of common stock.
• The transaction occurred on February 24, 2026, with the RSUs vesting on February 19, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as it signifies a director increasing their direct ownership in the company through a routine compensation mechanism, aligning interests with shareholders.

Positives

• Director Charles W. Newhall III increased his direct ownership of Supernus common stock by 4,475 shares.
• The conversion of Restricted Stock Units into common stock indicates a routine vesting event, aligning director interests with shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine RSU vesting and conversion transactions are common for directors and executives as part of their compensation packages, aligning their long-term interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to increased direct stock ownership.

Key Dates

Recommendation

The filing details a routine conversion of restricted stock units into common stock by a director, which increases their direct ownership. While this is a positive for insider alignment, it does not provide new operational or financial information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Director Ownership, Equity Compensation